With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2031-23-4,1-(3-Chloropropyl)-4-methylpiperazine dihydrochloride,as a common compound, the synthetic route is as follows.
EXAMPLE 183 4-Anilino-5-bromo-2-{4-[3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine A mixture of potassium carbonate (180 mg, 1.3 mmol), 4-anilino-5-bromo-2-(4-hydroxyanilino)pyrimidine (Method 4, 150 mg, 0.42 mmol) and 3-(4-methyl-1-piperazinyl)propyl chloride dihydrochloride (120 mg, 0.48 mmol) in DMSO (2 ml) was heated at 100 C. for 12 hours. Silica (1 g) was added and volatile material was removed by evaporation. The residue was loaded onto a Varian Mega Bond Elut column and the column was eluted with 50:50 iso-hexane: DCM (2*20 ml), DCM (2*20 ml), 2% 2M NH3/MeOH/DCM (2*20 ml), 4% 2M NH3/MeOH/DCM (2*20 ml), 6% 2M NH3/MeOH/DCM (2*20 ml) and 10% 2M NH3/MeOH/DCM (8*20 ml). Concentration of the appropriate fractions gave the product as a yellow solid (35 mg, 17%). MS (MH+): 497, 499; HPLC (RT): 2.74.
2031-23-4, As the paragraph descriping shows that 2031-23-4 is playing an increasingly important role.
Reference£º
Patent; AstraZeneca AB; US6593326; (2003); B1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics